Articles Related to NSCLC
Cisplatin-Gemcitabine Related Cardiomyopathy in Non-Small Cell Lung Cancer NSCLC Patient: A Case Study
Gemcitabine is a pyrimidine analog and cisplatin is a platinum agent, they are usually combined to form a chemotherapeutic doublet used to treat different types of oncological cancers, including non-small cell lung cancer (NSCLC). Although these agents are not known to cause such events, few cases related to possible cardiotoxicity side effects have been reported ; including angina, chronic heart failure, arrhythmias, and cardiac ischemia. A 52-year-old African male presented with Stage IV lung adenocarcinoma metastatic to the bone, pleura and lymph node, EGFR wild type. Patient has a history of hypertension, diabetes, and atrial fibrillation and on rate control medications. He was treated initially with cisplatin-gemcitabine, after which he developed cardiomyopathy.
Overuse and Misuse of Adjuvant Chemotherapy for Stages I and II Non-Small Cell Lung Cancer Chemotherapy: Empirical Findings from a Privately Insured Population
Among persons with early stage non-small cell lung cancer (NSCLC) resected for cure, appropriate use of adjuvant chemotherapy is an important additional determinant of survival. Oncology quality improvement initiatives focus on reducing overuse, underuse, and misuse.
The DNA mismatch repair (MMR) system is necessary for the maintenance of genomic stability. The MMR system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops (IDLs) and heterologies generated during DNA replication and recombination.